

Multiple Myelom (MM)

Erstlinie

DSMM XVII (geplant Q4 2018)

fit für autologe Transplantation

KRd
vs.
KRd + Elo

⇒ HD Mel

R
vs.
R + Elo

PD Dr. med. Stefan Wilop
swilop@ukaachen.de
Tel: 0241-8036461

Rezidiv/Progress

ab 3. Linie

AMG 176

Phase 1 First in Human
Study
Safety, Tolerability, PK, PD

AMG 176 (MCL-1 Inhibitor)

Dr. med. Deniz Gezer
dgezer@ukaachen.de
Tel: 0241-8037225

AMETHYST

Phase 1 First in Human
Study
Safety, Tolerability, PK, PD

Pegyliertes liposomales
Dexamethason

AZD4573

Phase 1 First in Human
Study
Safety, Tolerability, PK,
PD

AZD4573 (CDK9 Inhibitor)